Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Gene | ATRX |
| Variant | loss |
| Impact List | unknown |
| Protein Effect | loss of function |
| Gene Variant Descriptions | ATRX loss indicates loss of the ATRX gene, mRNA, and protein. |
| Associated Drug Resistance | |
| Category Variants Paths |
ATRX mutant ATRX inact mut ATRX loss |
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06478212 | Phase Ib/II | Temozolomide + Vorasidenib | Vorasidenib in Combination With Temozolomide (TMZ) in IDH-mutant Glioma | Active, not recruiting | USA | NLD | ITA | ISR | GBR | FRA | ESP | DEU | AUT | 2 |
| NCT05076513 | Phase I | Niraparib | Trial of Niraparib in Participants With Newly-diagnosed Glioblastoma and Recurrent Glioma | Active, not recruiting | USA | 0 |
| NCT05076513 | Phase I | Niraparib | Trial of Niraparib in Participants With Newly-diagnosed Glioblastoma and Recurrent Glioma | Active, not recruiting | USA | 0 |